Global Vector-Based RNAi Market Research Report 2023

Publication ID:

PB503232958

Publication Date:

March 1, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
Highlights
The global Vector-Based RNAi market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Vector-Based RNAi is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Vector-Based RNAi is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Vector-Based RNAi include Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vector-Based RNAi, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vector-Based RNAi.
The Vector-Based RNAi market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Vector-Based RNAi market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vector-Based RNAi manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals
Segment by Type
siRNA Design
siRNA Vectors
Custom siRNA Construction
Segment by Application
Hospitals
Speciality Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vector-Based RNAi in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Vector-Based RNAi Market Overview
1.1 Product Overview and Scope of Vector-Based RNAi
1.2 Vector-Based RNAi Segment by Type
1.2.1 Global Vector-Based RNAi Market Value Comparison by Type (2023-2029)
1.2.2 siRNA Design
1.2.3 siRNA Vectors
1.2.4 Custom siRNA Construction
1.3 Vector-Based RNAi Segment by Application
1.3.1 Global Vector-Based RNAi Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Speciality Clinics
1.4 Global Vector-Based RNAi Market Size Estimates and Forecasts
1.4.1 Global Vector-Based RNAi Revenue 2018-2029
1.4.2 Global Vector-Based RNAi Sales 2018-2029
1.4.3 Global Vector-Based RNAi Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Vector-Based RNAi Market Competition by Manufacturers
2.1 Global Vector-Based RNAi Sales Market Share by Manufacturers (2018-2023)
2.2 Global Vector-Based RNAi Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Vector-Based RNAi Average Price by Manufacturers (2018-2023)
2.4 Global Vector-Based RNAi Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Vector-Based RNAi, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vector-Based RNAi, Product Type & Application
2.7 Vector-Based RNAi Market Competitive Situation and Trends
2.7.1 Vector-Based RNAi Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Vector-Based RNAi Players Market Share by Revenue
2.7.3 Global Vector-Based RNAi Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Vector-Based RNAi Retrospective Market Scenario by Region
3.1 Global Vector-Based RNAi Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Vector-Based RNAi Global Vector-Based RNAi Sales by Region: 2018-2029
3.2.1 Global Vector-Based RNAi Sales by Region: 2018-2023
3.2.2 Global Vector-Based RNAi Sales by Region: 2024-2029
3.3 Global Vector-Based RNAi Global Vector-Based RNAi Revenue by Region: 2018-2029
3.3.1 Global Vector-Based RNAi Revenue by Region: 2018-2023
3.3.2 Global Vector-Based RNAi Revenue by Region: 2024-2029
3.4 North America Vector-Based RNAi Market Facts & Figures by Country
3.4.1 North America Vector-Based RNAi Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Vector-Based RNAi Sales by Country (2018-2029)
3.4.3 North America Vector-Based RNAi Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vector-Based RNAi Market Facts & Figures by Country
3.5.1 Europe Vector-Based RNAi Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Vector-Based RNAi Sales by Country (2018-2029)
3.5.3 Europe Vector-Based RNAi Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vector-Based RNAi Market Facts & Figures by Country
3.6.1 Asia Pacific Vector-Based RNAi Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Vector-Based RNAi Sales by Country (2018-2029)
3.6.3 Asia Pacific Vector-Based RNAi Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Vector-Based RNAi Market Facts & Figures by Country
3.7.1 Latin America Vector-Based RNAi Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Vector-Based RNAi Sales by Country (2018-2029)
3.7.3 Latin America Vector-Based RNAi Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
3.8.1 Middle East and Africa Vector-Based RNAi Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Vector-Based RNAi Sales by Country (2018-2029)
3.8.3 Middle East and Africa Vector-Based RNAi Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vector-Based RNAi Sales by Type (2018-2029)
4.1.1 Global Vector-Based RNAi Sales by Type (2018-2023)
4.1.2 Global Vector-Based RNAi Sales by Type (2024-2029)
4.1.3 Global Vector-Based RNAi Sales Market Share by Type (2018-2029)
4.2 Global Vector-Based RNAi Revenue by Type (2018-2029)
4.2.1 Global Vector-Based RNAi Revenue by Type (2018-2023)
4.2.2 Global Vector-Based RNAi Revenue by Type (2024-2029)
4.2.3 Global Vector-Based RNAi Revenue Market Share by Type (2018-2029)
4.3 Global Vector-Based RNAi Price by Type (2018-2029)
5 Segment by Application
5.1 Global Vector-Based RNAi Sales by Application (2018-2029)
5.1.1 Global Vector-Based RNAi Sales by Application (2018-2023)
5.1.2 Global Vector-Based RNAi Sales by Application (2024-2029)
5.1.3 Global Vector-Based RNAi Sales Market Share by Application (2018-2029)
5.2 Global Vector-Based RNAi Revenue by Application (2018-2029)
5.2.1 Global Vector-Based RNAi Revenue by Application (2018-2023)
5.2.2 Global Vector-Based RNAi Revenue by Application (2024-2029)
5.2.3 Global Vector-Based RNAi Revenue Market Share by Application (2018-2029)
5.3 Global Vector-Based RNAi Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck & Co.
6.1.1 Merck & Co. Corporation Information
6.1.2 Merck & Co. Description and Business Overview
6.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck & Co. Vector-Based RNAi Product Portfolio
6.1.5 Merck & Co. Recent Developments/Updates
6.2 Phio Pharmaceutical
6.2.1 Phio Pharmaceutical Corporation Information
6.2.2 Phio Pharmaceutical Description and Business Overview
6.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Phio Pharmaceutical Vector-Based RNAi Product Portfolio
6.2.5 Phio Pharmaceutical Recent Developments/Updates
6.3 Quark Pharmaceuticals
6.3.1 Quark Pharmaceuticals Corporation Information
6.3.2 Quark Pharmaceuticals Description and Business Overview
6.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Quark Pharmaceuticals Vector-Based RNAi Product Portfolio
6.3.5 Quark Pharmaceuticals Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Thermo Fisher Scientific Vector-Based RNAi Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 Silence Therapeutics
6.5.1 Silence Therapeutics Corporation Information
6.5.2 Silence Therapeutics Description and Business Overview
6.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Silence Therapeutics Vector-Based RNAi Product Portfolio
6.5.5 Silence Therapeutics Recent Developments/Updates
6.6 Qiagen NV
6.6.1 Qiagen NV Corporation Information
6.6.2 Qiagen NV Description and Business Overview
6.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Qiagen NV Vector-Based RNAi Product Portfolio
6.6.5 Qiagen NV Recent Developments/Updates
6.7 Ionis Pharmaceutical
6.6.1 Ionis Pharmaceutical Corporation Information
6.6.2 Ionis Pharmaceutical Description and Business Overview
6.6.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ionis Pharmaceutical Vector-Based RNAi Product Portfolio
6.7.5 Ionis Pharmaceutical Recent Developments/Updates
6.8 Dicerna Pharmaceuticals
6.8.1 Dicerna Pharmaceuticals Corporation Information
6.8.2 Dicerna Pharmaceuticals Description and Business Overview
6.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio
6.8.5 Dicerna Pharmaceuticals Recent Developments/Updates
6.9 Arrowhead Pharmaceuticals
6.9.1 Arrowhead Pharmaceuticals Corporation Information
6.9.2 Arrowhead Pharmaceuticals Description and Business Overview
6.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio
6.9.5 Arrowhead Pharmaceuticals Recent Developments/Updates
6.10 Arcturus Therapeutics
6.10.1 Arcturus Therapeutics Corporation Information
6.10.2 Arcturus Therapeutics Description and Business Overview
6.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Arcturus Therapeutics Vector-Based RNAi Product Portfolio
6.10.5 Arcturus Therapeutics Recent Developments/Updates
6.11 Alnylam Pharmaceuticals
6.11.1 Alnylam Pharmaceuticals Corporation Information
6.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Description and Business Overview
6.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio
6.11.5 Alnylam Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vector-Based RNAi Industry Chain Analysis
7.2 Vector-Based RNAi Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vector-Based RNAi Production Mode & Process
7.4 Vector-Based RNAi Sales and Marketing
7.4.1 Vector-Based RNAi Sales Channels
7.4.2 Vector-Based RNAi Distributors
7.5 Vector-Based RNAi Customers
8 Vector-Based RNAi Market Dynamics
8.1 Vector-Based RNAi Industry Trends
8.2 Vector-Based RNAi Market Drivers
8.3 Vector-Based RNAi Market Challenges
8.4 Vector-Based RNAi Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂